Detalhe da pesquisa
1.
Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies.
Oncologist
; 23(2): 159-170, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29118268
2.
Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia.
Haematologica
; 103(1): 101-106, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29097499
3.
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
Lancet Oncol
; 17(4): 496-508, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26968357
4.
MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.
Blood
; 124(7): 1183-91, 2014 Aug 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-24963042
5.
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Hematol Oncol
; 33(2): 57-66, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24777753
6.
A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial.
Haematologica
; 98(7): 1067-72, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23585522
7.
Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial.
Haematologica
; 98(9): 1421-3, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23812932
8.
Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.
Leuk Lymphoma
; 64(3): 525-539, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36370098
9.
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML.
Blood Adv
; 6(7): 2219-2229, 2022 04 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34933333
10.
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes.
Blood Adv
; 6(7): 2207-2218, 2022 04 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34972214
11.
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.
Cancer
; 117(12): 2697-702, 2011 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21656747
12.
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.
Blood
; 114(13): 2764-73, 2009 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-19546476
13.
Forsaken Pharmaceutical: Glasdegib in Acute Myeloid Leukemia and Myeloid Diseases.
Clin Lymphoma Myeloma Leuk
; 21(4): e415-e422, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33547022
14.
Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies.
Hemasphere
; 5(4): e549, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33718803
15.
Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes.
J Clin Oncol
; 39(13): 1426-1436, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33764805
16.
Discontinuous drug binding to proteins: binding of an antineoplastic benzyl styryl sulfone to albumin and enzymes in vitro and in phase I clinical trials.
Drug Metab Dispos
; 38(9): 1480-5, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20501913
17.
Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*.
Eur J Haematol
; 85(2): 130-8, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20394651
18.
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
Lancet Oncol
; 10(3): 223-32, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19230772
19.
Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia.
Leuk Res
; 97: 106430, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32763582
20.
Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study.
Leuk Res
; 94: 106369, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32442785